Back to search results

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

T-Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Yale Smilow Cancer Hospital, New Haven, Connecticut, United States

    Contact: Study coordinator (Daniel Moncayo) · daniel.moncayo@yale.edu · 2035000834
    Contact: Principal Investigator (Tarsheen Sethi, MD)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Joanne Charles) · Joanne_Charles@DFCI.HARVARD.EDU · 857-215-2961
    David Fisher, MD (Sub-investigator)
Study leads

  • Tarsheen Sethi, MD

    Principal Investigator

    Yale University

View source on ClinicalTrials.gov(opens in a new tab)